|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the kidney, NXT reduced mesangial matrix expansion and glomerulosclerosis by inhibiting extracellular matrix accumulation through activation of matrix metalloproteinase 2/9 and inactivating transforming growth factor β1 expression.
|
31545275 |
2019 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Renal histology in untreated mice showed mesangial proliferation and progressive glomerulosclerosis with tubular atrophy, and increased expression of transforming growth factor β1 (TGF-β1), monocyte chemoattractant protein-1 (MCP-1), α-smooth muscle actin (α-SMA), fibronectin (FN) and collagen.
|
31358596 |
2019 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low dose US Food and Drug Administration (FDA)-approved MEK/ERK inhibitor trametinib/GSK1120212 blunted TGF-β1-induced mTORC1 activation in podocytes, ameliorated up-regulation of TGF-β, plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, fibronectin and α-smooth muscle actin and prevented albuminuria and glomerulosclerosis with improved serum albumin.
|
31377057 |
2019 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Western blotting and immunohistochemistry revealed that R406 treatment significantly delayed the appearance of proteinuria, histologically improved their glomerulosclerosis and inhibited the increased the expression of MCP-1 and TGF-β1 mRNAs and the nephrin and podocin proteins in the kidney.
|
28479222 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In treatment studies, steroids prevented glomerulosclerosis in the anti-GBM model in contrast to angiotensin II inhibition, which lacked a protective effect, and urinary podocyte and TGF-β1 mRNA markers more accurately reflected both the amount of podocyte depletion and the degree of glomerulosclerosis compared with proteinuria under both scenarios.
|
28419296 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transforming growth factor beta 1 (TGF-β1) plays a critical role in the pathogenesis of glomerulosclerosis.
|
28719898 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TGF-β1 induced by glomerulosclerosis impairs the protein expression of nephrin and amplifies the protein expression of desmin and caspase -9 via TRPC6 signal pathway.
|
28214865 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The profibrotic cytokine transforming growth factor beta 1 (TGF-β1) plays a central role in the development of glomerular sclerosis.
|
27826032 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that TBX3 acts as an anti-apoptotic factor in MC in vitro and may be involved in the mechanism by which TGF-β1 induces glomerulosclerosis and tubular fibrosis during the progression of nephropathies.
|
25158279 |
2014 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher transforming growth factor-β1 and severe chronic vasculopathy (but not glomerulosclerosis, interstitial fibrosis or lymphocyte infiltrate) were associated with the IgAN progression 24 months after biopsy.
|
20650904 |
2011 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TGF-beta1 reduces WT1 expression in cultured human podocytes and podocytes in mice before overt glomerulosclerosis begins.
|
21378152 |
2011 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study clearly provided in vivo evidence for the AngII-independent MAPK activation by human (pro)renin receptor and induction of glomerulosclerosis with increased TGF-beta1 expression.
|
17494887 |
2007 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Homozygosity for Arg25 was also associated with severity of proteinuria at diagnosis (p = 0.038), plasma TGF-beta1 protein levels (p = 0.01), and severity of glomerulosclerosis (p = 0.04).
|
15942255 |
2005 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One major subgroup of the samples expressed fibrosis-related genes that correlated with pathological evidence of glomerulosclerosis; however, decreased expression of TGF-beta1 argued against its role in lupus renal fibrosis.
|
15199407 |
2004 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the mRNA splicing patterns for EDA+ and EDB+ fibronectin were investigated in vivo in various experimental sclerotic glomerulopathies, in vitro in rat mesangial cells (MC) that were stimulated by TGFbeta or transfected with IL-4, and in human kidney biopsies with GS from patients with various kidney diseases.
|
15372454 |
2004 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transforming growth factor-beta1 (TGF-beta1) is a profibrotic cytokine suspected to be a crucial factor underlying glomerulosclerosis in advanced diabetic nephropathy.
|
12500218 |
2003 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At 28 to 30 months the glomerulosclerosis was diffuse and increased levels of type I and type IV collagen and transforming growth factor-beta 1 mRNA were present.
|
12651625 |
2003 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although the pathogenetic relevance of transforming growth factor-beta (TGF-beta) to glomerulosclerosis is well established, it is not known whether a signal transduction cascade of TGF-beta is involved in the development of focal segmental glomerulosclerosis (FSGS), nor is it clear how TGF-beta 1 is activated during the course of FSGS formation.
|
14531804 |
2003 |
|
Glomerulosclerosis (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.
|
12466133 |
2002 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report that podocytes undergo apoptosis at early stages in the course of progressive glomerulosclerosis in TGF-beta1 transgenic mice.
|
11560950 |
2001 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The degree of glomerulosclerosis in each group followed the TGF-beta1/beta-actin mRNA ratios indicating that the level is the major determinant ofglomerulosclerosis but not the disease entities.
|
9375822 |
1997 |
|
Glomerulosclerosis (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that TGF-beta 1 is involved in glomerulosclerosis and the development of tubulointerstitial lesions, indicating its potential importance in the progression and aggravation of immunoglobulin A nephropathy.
|
9100161 |
1997 |